NetworkNewsBreaks – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) Shares Higher on Encouraging Top-line Data from Trial of Ocular Bandage Gel
Shares of EyeGate Pharmaceuticals (NASDAQ: EYEG) are up more than 15% mid-day following topline results from the first-in-human pilot trial of the company’s EyeGate Ocular Bandage Gel (EyeGate OBG) in corneal epithelial effects. The study enrolled 39 subjects undergoing bilateral photorefractive keratectomy surgery to assess the safety and performance of EyeGate OBG on its own or combined with a bandage contact lens (BCL) compared to the current standard of care, artificial tears and BCL. The study demonstrated safety and tolerability of EyeGate OBG, with encouraging potential efficacy. “Corneal epithelial defects represent a large, underserved market with no approved eye drops…







